US Stock MarketDetailed Quotes
LABP Landos Biopharma
- 22.4450
- +0.2400+1.08%
Trading May 14 11:41 ET
70.16MMarket Cap-5611P/E (TTM)
22.4800High22.2500Low1.67KVolume22.4800Open22.2050Pre Close37.28KTurnover0.13%Turnover RatioLossP/E (Static)3.13MShares22.840052wk High3.03P/B29.85MFloat Cap2.500052wk Low--Dividend TTM1.33MShs Float169.8900Historical High--Div YieldTTM1.04%Amplitude2.1110Historical Low22.3910Avg Price1Lot Size
Landos Biopharma Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 43.46%9.3M | -43.97%22.73M | 1.49%6.61M | -33.59%5.2M | -60.60%4.44M | -56.67%6.48M | -28.61%40.56M | -68.07%6.51M | -36.88%7.83M | -20.20%11.27M |
| Selling and administrative expenses | 94.86%6.14M | -27.91%10.73M | 11.75%3.46M | -28.01%2.14M | -57.61%1.98M | -24.08%3.15M | -2.43%14.88M | -55.42%3.1M | -3.01%2.97M | 79.58%4.66M |
| -General and administrative expense | 94.86%6.14M | -27.91%10.73M | 11.75%3.46M | -28.01%2.14M | -57.61%1.98M | -24.08%3.15M | -2.43%14.88M | -55.42%3.1M | -3.01%2.97M | 79.58%4.66M |
| Research and development costs | -5.26%3.15M | -53.27%12M | -7.82%3.15M | -37.00%3.06M | -62.70%2.46M | -69.20%3.33M | -38.22%25.68M | -74.61%3.41M | -47.97%4.86M | -42.68%6.6M |
| Operating profit | -43.46%-9.3M | 43.97%-22.73M | -1.49%-6.61M | 33.59%-5.2M | 60.60%-4.44M | 56.67%-6.48M | -4.50%-40.56M | 68.07%-6.51M | 36.88%-7.83M | -390.21%-11.27M |
| Net non-operating interest income expense | -10.69%401K | -33.60%836K | -61.90%488K | -882.09%-658K | 1,395.35%557K | 410.23%449K | 205.58%1.26M | 1.28M | -67K | -43K |
| Non-operating interest income | -10.69%401K | -33.60%836K | ---- | ---- | ---- | --449K | 205.58%1.26M | ---- | ---- | ---- |
| Total other finance cost | ---- | ---- | ---- | 882.09%658K | -1,395.35%-557K | ---- | ---- | ---- | --67K | --43K |
| Other net income (expense) | 25.00%-3K | -269.23%-44K | 3K | -3K | -260.00%-40K | -500.00%-4K | 244.44%26K | 0 | -88.37%25K | |
| Gain on sale of security | 25.00%-3K | -269.23%-44K | --3K | ---3K | -260.00%-40K | -500.00%-4K | 244.44%26K | --0 | ---- | 600.00%25K |
| Income before tax | -47.45%-8.9M | 44.15%-21.94M | -16.95%-6.12M | 25.79%-5.86M | 65.24%-3.92M | 59.41%-6.03M | -2.22%-39.28M | 73.97%-5.23M | 37.35%-7.9M | -375.42%-11.28M |
| Income tax | ||||||||||
| Net income | -47.45%-8.9M | 44.15%-21.94M | -16.95%-6.12M | 25.79%-5.86M | 65.24%-3.92M | 59.41%-6.03M | -2.22%-39.28M | 73.97%-5.23M | 37.35%-7.9M | -375.42%-11.28M |
| Net income continuous Operations | -47.45%-8.9M | 44.15%-21.94M | -16.95%-6.12M | 25.79%-5.86M | 65.24%-3.92M | 59.41%-6.03M | -2.22%-39.28M | 73.97%-5.23M | 37.35%-7.9M | -375.42%-11.28M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -47.45%-8.9M | 44.15%-21.94M | -16.95%-6.12M | 25.79%-5.86M | 65.24%-3.92M | 59.41%-6.03M | -2.22%-39.28M | 73.97%-5.23M | 37.35%-7.9M | -375.42%-11.28M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -47.45%-8.9M | 44.15%-21.94M | -16.95%-6.12M | 25.79%-5.86M | 65.24%-3.92M | 59.41%-6.03M | -2.22%-39.28M | 73.97%-5.23M | 37.35%-7.9M | -375.42%-11.28M |
| Basic earnings per share | -53.76%-1.43 | 64.14%-3.5 | 23.85%-0.99 | 52.04%-0.94 | 77.50%-0.63 | 74.86%-0.93 | 4.31%-9.76 | 75.00%-1.3 | 38.75%-1.96 | -333.33%-2.8 |
| Diluted earnings per share | -53.76%-1.43 | 64.14%-3.5 | 23.85%-0.99 | 52.04%-0.94 | 77.50%-0.63 | 74.86%-0.93 | 4.31%-9.76 | 75.00%-1.3 | 38.75%-1.96 | -333.33%-2.8 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg